Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
HKG: 0512
Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...
China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...